Hologic, Inc. (NASDAQ:HOLX) Shares Sold by APG Asset Management US Inc.

APG Asset Management US Inc. lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 64,024 shares of the medical equipment provider’s stock after selling 4,081 shares during the quarter. APG Asset Management US Inc.’s holdings in Hologic were worth $4,744,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. AQR Capital Management LLC lifted its holdings in Hologic by 1.5% in the second quarter. AQR Capital Management LLC now owns 565,955 shares of the medical equipment provider’s stock worth $42,022,000 after purchasing an additional 8,441 shares during the period. Squarepoint Ops LLC boosted its holdings in shares of Hologic by 251.9% in the second quarter. Squarepoint Ops LLC now owns 58,880 shares of the medical equipment provider’s stock valued at $4,372,000 after acquiring an additional 97,634 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its holdings in shares of Hologic by 56.9% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 44,963 shares of the medical equipment provider’s stock valued at $3,339,000 after acquiring an additional 16,307 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Hologic during the second quarter valued at approximately $39,427,000. Finally, Lombard Odier Asset Management Europe Ltd bought a new stake in Hologic during the second quarter worth approximately $10,184,000. Institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the subject of several recent research reports. JPMorgan Chase & Co. increased their target price on shares of Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. Stephens restated an “overweight” rating and set a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Royal Bank of Canada reiterated a “sector perform” rating and set a $82.00 price objective on shares of Hologic in a report on Friday, August 16th. StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research note on Friday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price target on shares of Hologic in a research note on Tuesday, September 17th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.60.

Insider Buying and Selling

In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now directly owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares in the company, valued at approximately $3,615,024. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now owns 3,735 shares in the company, valued at $310,415.85. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,280 shares of company stock valued at $1,469,973. 1.75% of the stock is owned by company insiders.

Hologic Stock Performance

Shares of HOLX opened at $80.10 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. Hologic, Inc. has a one year low of $64.02 and a one year high of $84.67. The company’s fifty day moving average price is $81.02 and its 200 day moving average price is $77.24. The company has a market capitalization of $18.69 billion, a PE ratio of 40.87, a price-to-earnings-growth ratio of 2.58 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same quarter last year, the firm posted $0.93 EPS. The company’s revenue was up 2.7% on a year-over-year basis. As a group, analysts expect that Hologic, Inc. will post 4.09 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.